15-2347
2-丙醇
≥99.7%, suitable for residue analysis, JIS 1000
别名:
IPA, 仲丙醇, 异丙醇
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
线性分子式:
(CH3)2CHOH
化学文摘社编号:
分子量:
60.10
EC Number:
200-661-7
UNSPSC Code:
12352001
PubChem Substance ID:
Beilstein/REAXYS Number:
635639
MDL number:
Assay:
≥99.7%
Bp:
82 °C (lit.)
Vapor pressure:
44 mmHg ( 25 °C), 33 mmHg ( 20 °C)
agency
JIS 1000
vapor density
2.1 (vs air)
vapor pressure
44 mmHg ( 25 °C), 33 mmHg ( 20 °C)
assay
≥99.7%
form
liquid
autoignition temp.
750 °F
expl. lim.
2.0-12.7 %, 93 °C
availability
available only in Japan
dilution
(for analytical testing)
refractive index
n20/D 1.377 (lit.)
bp
82 °C (lit.)
mp
−89.5 °C (lit.)
density
0.785 g/mL at 25 °C (lit.)
suitability
suitable for residue analysis
SMILES string
CC(C)O
InChI
1S/C3H8O/c1-3(2)4/h3-4H,1-2H3
InChI key
KFZMGEQAYNKOFK-UHFFFAOYSA-N
Still not finding the right product?
Explore all of our products under 2-丙醇
signalword
Danger
hcodes
Hazard Classifications
Eye Irrit. 2 - Flam. Liq. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
3 - Flammable liquids
wgk
WGK 1
flash_point_f
53.6 °F - closed cup
flash_point_c
12.0 °C - closed cup
ppe
Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter
法规信息
新产品
此项目有
Peter C Grayson et al.
Arthritis & rheumatology (Hoboken, N.J.), 67(7), 1922-1932 (2015-04-22)
To discover biomarkers involved in the pathophysiology of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and to determine whether low-density granulocytes (LDGs) contribute to gene expression signatures in AAV. The source of clinical data and linked biologic specimens was a randomized controlled
Thomas W Winkler et al.
PLoS genetics, 11(10), e1005378-e1005378 (2015-10-02)
Genome-wide association studies (GWAS) have identified more than 100 genetic variants contributing to BMI, a measure of body size, or waist-to-hip ratio (adjusted for BMI, WHRadjBMI), a measure of body shape. Body size and shape change as people grow older
Jan Rybniker et al.
Nature communications, 6, 7659-7659 (2015-07-15)
Better antibiotics capable of killing multi-drug-resistant Mycobacterium tuberculosis are urgently needed. Despite extensive drug discovery efforts, only a few promising candidates are on the horizon and alternative screening protocols are required. Here, by testing a panel of FDA-approved drugs in